期刊
CLINICAL LIPIDOLOGY
卷 4, 期 5, 页码 595-609出版社
FUTURE MEDICINE LTD
DOI: 10.2217/CLP.09.49
关键词
atherosclerosis; cholesterol; insulin resistance; lipoproteins; serine palmitoyltransferase; sphingomyelin; sphingomyelin synthase; sphingomyelin-rich microdomains (lipid rafts)
资金
- American Heart Association Heritage Affiliate
- National Institute of Health [HL-64735, HL-69817]
The ability to regulate sphingomyelin (SM) biosynthesis could become a promising treatment for atherosclerosis. SM is one of the major lipid components in plasma and cell membranes. We have found that plasma SM level is an independent risk factor for coronary artery disease. Thus, SM levels have a clinically important impact on lipoprotein metabolism. We have also found that reduction of plasma and liver SM, with concomitant reduction of atherosclerosis, could be achieved by pharmacological inhibition of serine palmitoyltransferase in a mouse model. Moreover, we also found SM synthase 2, the last enzyme for SM biosynthesis, deficiency in macrophages decreases SM levels on plasma membrane and, thus, decreases atherosclerosis in a mouse model. These observations emphasize the need for a better understanding of SM metabolism. This review mainly focuses on the relationship between SM de novo synthesis, lipid metabolism and atherosclerosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据